N@N

ImmunoCellular Therapeutics Ltd (OTCBB:IMUC), Up By 6.52% ($0.15) After BUYINS.NET SqueezeTrigger Report Released on Thursday,

^{Published on 2013-04-05 07:46:06 - WOPRAI}
 

April 5, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Thursday, April 4th 2013 at 07:16:00 PDT stating that ImmunoCellular Therapeutics Ltd (OTCBB:IMUC) was expected to be Up After it crossed above its SqueezeTrigger Price of 2.25 on Thursday, April 4th 2013. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=imuc&id=358766

From August 2009 to March 2013, an aggregate amount of 61069937 shares of IMUC have been shorted for a total dollar value of $122139874. The IMUC SqueezeTrigger price of $2.25 is the volume weighted average price that all shorts are short in shares of IMUC. There is still approximately $8,116,116 of potential short covering in shares of IMUC.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

ImmunoCellular Therapeutics Ltd (OTCBB:IMUC) - ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company, focuses on developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumor cancers. Its product candidate portfolio consists of cellular immunotherapies targeting cancer and cancer stem cell antigens; peptide based immunotherapies targeting cancer stem cells; and monoclonal antibodies to diagnose and treat cancers, such as such as glioblastoma multiforme (GBM), ovarian cancer, small-cell lung cancer, and pancreatic cancer. The company s lead product candidate, ICT-107, is a dendritic cell-based vaccine that is in Phase II clinical trial targeting multiple tumor associated antigens for GBM, a particularly lethal type of brain cancer. It also engages in developing ICT-121, a CD-133 targeting cancer stem cell vaccine in pre-clinical development stage to treat GBM, pancreatic cancer, and other solid tumor cancers; and ICT-140, a dendritic cell-based vaccine targeting cancer stem cells and cancer antigens in pre-clinical development stage for the treatment of ovarian cancer. In addition, the company is developing various monoclonal antibody product candidates, including ICT-109, ICT-037, ICT-69, and ICT-Diagnostic-SCLC, which are in pre-clinical development stage to treat small cell lung cancer, lung and colon cancer, pancreatic cancer, multiple myeloma, and ovarian cancer. ImmunoCellular Therapeutics, Ltd. is based in Woodland Hills, California..

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net